OCT 09, 2019 10:30 AM PDT

Newly Diagnosed Ovarian Cancer: Surgical Options

Speaker
  • Full-time faculty member, Department of Gynecologic Oncology, Moffitt Cancer Center, and Professor, USF Morsani College of Medicine
    BIOGRAPHY

Abstract

A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortunately, the majority of women with ovarian cancer present with advanced disease due to widespread intraperitoneal metastases. The surgical management of advanced ovarian cancer has undergone dramatic transformations over the past 20 years and that will be the focus of this presentation. A large body of retrospective data accumulated which indicated that women undergoing cytoreductive surgery for ovarian cancer did much better if all gross disease was resected (“R0”). Based on this, radical upper abdominal surgery to achieve R0 has been adopted into management. Many patients with advanced ovarian cancer are too ill or too advanced for surgery. Such patients are frequently do receive treatment with chemotherapy. It was recognized that many such patients respond well with subsequent improvement in performance status and operability. Based on this, data accumulated on management with neoadjuvant chemotherapy followed by interval cytoreductive surgery for selected patients. This data led to a series of prospective, randomized trials which demonstrated non-inferiority (when compared to primary cytoreductive surgery), along with a reduction in morbidity. Based on this, clinical practice guidelines (combined SGO/ASCO) were published in 2016 (Wright AA, et al.. Gynecol Oncol 2016; 143: 3-15) for primary management of women with advanced ovarian cancer that included evaluation by gynecologic oncologist, imaging with CT scan, utilization of neoadjuvant chemotherapy for women at high risk for surgery or low likelihood of achieving optimal cytoreduction, and histologic confirmation prior to initiation of neoadjuvant chemotherapy.

Learning objectives:

1. To gain an understanding of the evolution over the past 20 years in the surgical management of primary advanced ovarian cancer.
2. To gain insight into the technical aspects of cytoreductive surgery for advanced ovarian cancer.


Show Resources
You May Also Like
FEB 15, 2023 7:00 AM PST
FEB 15, 2023 7:00 AM PST
Date: February 15, 2023 Time: 7:00am (PST), 10:00pm (EST), 4:00pm (CET) While not all microscopy samples can fluoresce, all can scatter light, and this scattered light can be imaged. This ha...
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
SEP 22, 2022 9:00 AM PDT
SEP 22, 2022 9:00 AM PDT
Date: September 22, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Optimizing platforms for surgical specimen collection and deep human phenotyping was used to enhance protein biomarke...
AUG 16, 2022 11:00 AM PDT
AUG 16, 2022 11:00 AM PDT
Date: August 16, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEST) Understanding genomic variation in the context of cancer is paramount to identifying disease drivers and informing pers...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
OCT 13, 2022 9:00 AM +08
OCT 13, 2022 9:00 AM +08
First Broadcast: Date: October 12, 2022 Time: 8:00am PDT, 11:00am EDT Second Broadcast: Date: October 12, 2022 Time: 9:00am SGT The new Embedded CryoSPARC Live, now fully integrated with t...
OCT 09, 2019 10:30 AM PDT

Newly Diagnosed Ovarian Cancer: Surgical Options



Show Resources
Loading Comments...
Show Resources
Attendees